TLPPF News and Press, Telix Pharmaceuticals Ltd From 08/23/23

2023-08-23 12:06:48 ET More on Telix Pharmaceuticals Eli Lilly inks licensing deal for cancer therapy with Australian biotech Telix Seeking Alpha Catalyst Watch Earnings data for Telix Pharmaceuticals For further details see: Telix Pharmaceuticals reports...

2023-04-17 14:33:31 ET Telix Pharmaceuticals press release ( OTCPK:TLPPF ): Q1 Revenue of A$100.1M. cash balance of A$121.4M Demand for Illuccix in the United States continues to increase with sales of $97.5M (up from $76.8M in the prior quarter) Second conse...

2023-04-17 01:35:00 ET Summary Pfizer announced a major partnership with Shanghai’s Sinopharm to market up to 12 innovative drugs in China over the next three years. Shanghai Junshi Biosciences said its PARP inhibitor met its primary efficacy endpoint as a maintenance thera...

Telix Pharmaceuticals press release ( OTCPK:TLPPF ): FY net loss after tax A$104.1M. Adjusted earnings before tax, interest, depreciation and amortisation -A$67.8M. Revenue of A$160.1M (vs. A$7.6M Y/Y). Cash and cash equivalents of A$116.3M as at 31 December 2022. F...

Telix Pharmaceuticals Limited press release ( OTCPK:TLPPF ): Q4 Revenue of $78.2M (+41.4% Q/Q). Net operating cash flow improved by $6.9M over the prior quarter to a $1.6M inflow for the quarter. Cash receipts from customers were $72.2M, up 62% from $44.5M...

Telix Pharmaceuticals press release ( OTCPK:TLPPF ): Q3 net operating cash outflow reduced by A$20.5M to A$5.3M, a significant reduction on the prior quarter ($25.8 million net operating cash outflow). Customer receipts of A$44.5M, up from A$5.4M in the previous quarter, ...

Telix Pharmaceuticals ( OTCPK:TLPPF ) on Thursday said that Health Canada approved Illuccix for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumor tissue in recurrent prostate cancer. Illuccix [kit for the preparation of gallium (...

Telix Pharmaceuticals Limited press release ( OTCPK:TLPPF ): Q2 Revenue of $22.5M (+1078.0% Y/Y). As of 30 June 2022, the company held cash reserves of $122.6M. The company has 5.5 quarters runway based on net cash used in operations in the June 2022 quarter. For fur...

A late-stage trial of Eli Lilly's (NYSE:LLY) lebrikizumab for atopic dermatitis showed significant improvement in measures of disease severity when combined with topical corticosteroids. After 16 weeks of treatment, 70% of patients with moderate-to-severe atopic dermatitis who received lebrik...

Australia-based Telix Pharmaceuticals (OTCPK:TLPPF) announced a license agreement with Eli Lilly (NYSE:LLY) on Monday for olaratumab, a cancer therapy sold under the brand name Lartruv. Per the terms, Telix gets exclusive worldwide rights to develop and commercialize the radiolabelled forms o...